Berenberg Bank restated their buy rating on shares of Abcam (LON:ABC) in a report published on Monday, Digital Look reports. They currently have a GBX 1,330 ($17.38) target price on the stock.

Separately, Peel Hunt reaffirmed an add rating and set a GBX 1,300 ($16.99) price target (down previously from GBX 1,430 ($18.69)) on shares of Abcam in a research note on Monday.

Abcam stock opened at GBX 1,146 ($14.97) on Monday. Abcam has a 12-month low of GBX 1,006 ($13.15) and a 12-month high of GBX 1,523 ($19.90). The company has a market capitalization of $2.38 billion and a price-to-earnings ratio of 41.08. The firm’s fifty day moving average price is GBX 1,222.48 and its 200 day moving average price is GBX 1,292.48.

The business also recently disclosed a dividend, which will be paid on Friday, November 29th. Shareholders of record on Thursday, November 7th will be issued a dividend of GBX 8.58 ($0.11) per share. This is a positive change from Abcam’s previous dividend of $3.55. This represents a yield of 0.74%. The ex-dividend date is Thursday, November 7th. Abcam’s dividend payout ratio (DPR) is currently 0.43%.

In related news, insider Alan Thomas Hirzel acquired 4,250 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of GBX 1,139 ($14.88) per share, with a total value of £48,407.50 ($63,252.97).

Abcam Company Profile

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with's FREE daily email newsletter.